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Abstract:
CELLULAR RESPONSE TO PROSTHETIC WEAR DEBRIS DIFFERS IN
RHEUMATOID VERSUS NON-RHEUMATOID ARTHRTIS. Anant Vasudevan,
Edward F. DiCarlo, Timothy Wright, Dan Chen, Mark. P Figgie, Steven R. Goldring,
Lisa A. Mandl. Department of Rheumatology, Hospital for Special Surgery, Weill
Cornell Medical College, New York, NY. (Sponsored by Carrie Swigart, Department of
Orthopaedics and Rehabilitation, Yale University School of Medicine).
In the setting of inflammatory arthritis, the histopathologic reaction to foreign
body wear debris generated from a failing arthroplasty has not been definitively
characterized. This study examined whether patients with rheumatoid arthritis (RA)
demonstrate different patterns of prosthetic wear or cellular responses to implant wear
debris compared to patients without inflammatory joint disease. Thirty-eight patients who
had a primary revision of a total elbow arthroplasty (TEA) for aseptic loosening between
1996 and 2008 were identified. Twenty-five had RA and 13 had no inflammatory
arthritis. Clinical data, gross wear patterns of the removed prostheses, and
histopathological analyses of peri-implant tissue were compared between RA and nonRA patients. Evaluation of the retrieved prostheses showed that conformational change of
the humeral polyethylene bushing was associated with the generation of polyethylene and
metal particles. The amount and type of wear debris in peri-prosthetic tissues was similar
in RA and non-RA patients. RA patients not on anti-tumor necrosis factor (TNF) therapy
exhibited a histologic pattern of interstitial and sheet-like lymphocytic infiltrates
associated with a high plasma cell composition, which was different from the
predominantly perivascular infiltrates with few plasma cells seen in non-RA patients (pvalue = 0.04). RA patients on anti-TNF therapy showed a mixed perivascular and
interstitial pattern of infiltrates with variable plasma cell composition. Based on this data,
we propose that RA patients exhibit a distinct cellular response to implant wear debris
compared with non-RA patients. This reaction was unrelated to differences in the type or
amount of wear debris and was mitigated by anti-TNF therapy. These results suggest an
intrinsic alteration in immunoregulation in RA and have implications for potential
immunologic treatment of osteolysis in these patients.
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Introduction
Rheumatoid Arthritis: Pathogenesis
Rheumatoid arthritis (RA) is a common systemic autoimmune disorder, with an estimated
population prevalence of 1%. It is characterized by persistent chronic inflammation,
which classically destroys the tissue and bone of diarthrodial joints, but also has multiple
systemic manifestations[1, 2]. The currently understood pathophysiology of RA is
multifaceted, involving a genetically encoded predisposition towards an aberrant
inflammatory response to both external and internal stimuli.
The post-translational modification known as citrullination facilitates an
autoimmune pathway that is thought to be a key pathophysiologic mechanism of RA. The
susceptibility to forming citrullinated proteins is most consistently linked with a genetic
predisposition in the HLA-DRB1 gene[3]. This gene is responsible for producing MHC
class II molecules involved in the presentation of peptides during the initiation of an
immune response. However, aberrant alleles at this locus, especially HLA-DRB1*04,
have been shown to create peptide-binding epitopes that preferentially bind citrullinated
proteins generated from self-antigens [4, 5]. Recognition of these auto-antigens then
precipitates a systemic autoimmune response. This response results in the formation of
antibodies against citrullinated proteins that is clinically measured by the presence of
anti-CCP (anti-cyclic citrullinated peptide) antibodies[3]. The current literature suggests
that anti-CCP positivity and negativity represent two distinct subsets of rheumatoid
arthritis[5-7].
Anti-CCP positive RA stems from both exogenous and endogenous factors, which
stimulate an autoimmune response towards citrullinated proteins. For example,

6
citrullinated fibrinogen and vimentin have been used in the literature to elicit an
autoimmune response through the HLA-DR1 shared epitope allele. Van de Woude et. al.
showed that in the presence of HLA-DR1 and a smoking history, antibodies directed
against vimentin conferred an odds ratio of 58 for RA compared to an odds ratio of 5.4 in
the absence of these antibodies [6]. These ratios were much closer in patients with
antibodies against fibrinogen[6]. Antibodies directed against citrullinated vimentin,
fibrinogen, and alpha-enolase in particular show limited cross-reactivity. Antibodies
against type II collagen appear to form in the absence of citrullination but again show
limited reactivity against other antigens. Positivity toward each of these possible triggers
appears to represent distinct subgroups of anti-CCP positive RA [5]. Such studies
indicate that a combination of genetic risk factors, environmental risk factors such as
smoking, and the presence of various citrullinated peptides together dictate the extent of
an autoimmune response that is linked to rheumatoid arthritis.
However, where these peptides come from or what causes them to form is less
clear. Snir et. al. demonstrated in RA patients that anti-CCP antibodies were present at
higher levels in the synovial fluid compared to the serum when compared to tetanus
toxoid controls, which were significantly higher in the serum. This point raises the
possibility that anti-CCP antibodies are locally produced at the site of inflammation and
rheumatologic disease [3, 5, 8]. Other studies have demonstrated ectopic lymphoid
structures and the presence of clonal B cell aggregates in the synovial tissue of RA
patients [3, 8]. Such findings are consistent with the production of anti-CCP antibodies
within the RA synovium.
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Furthermore, alpha-enolase is a glycolytic enzyme that has been found in the
joints of patients with multiple types of inflammatory arthritis. Citrullinated alphaenolase (CEP), however, has been associated more with RA, leading to an interest in antiCEP antibodies as a more specific subset of anti-CCP antibodies for disease detection.
One study indicated that anti-CEP antibodies have up to a 97% specificity for RA [9].
Mahdi et. al. recently published a study linking the presence of CEP to smoking. The
mechanism of this process is unclear but smoking has also been independently associated
with anti-CCP positivity[9]. The formation of anti-CEP antibodies is associated with the
BRD 2 gene [9]. Studies also show that the concurrent presence of the HLA-DR1 shared
epitope, a smoking history, and the PTPN22 gene is linked to anti-CEP positivity[3].
Comparatively less can be surmised about the pathogenesis of anti-CCP antibody
negative RA. Though prior studies had indicated that the HLA-DR1*03 locus is
associated with the autoantibody negative subset of RA, more recent studies have not
found a statistically significant association[10]. A recent study looked at a genome-wide
association of both HLA and non-HLA genes in RA patients with and without anti-CCP
antibody positivity. The most significant difference between antibody positive and
negative patients was on chromosome 6 in the HLA region. Of note, two non-HLA genes
associated with anti-CCP antibody negative RA were identified: rs4305317 and
rs6448119. The former is considered to be the best candidate gene with specificity for
anti-CCP antibody negative RA [7]. However, before insight can be gained into this
subset of RA, further studies corroborating the identification of this candidate gene are
needed.
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Rheumatoid Arthritis: A review of known immunopathology
As a disease entity whose pathogenesis involves autoantibody production by
plasma cells, RA mediates inflammation by involving components of both the innate and
adaptive immune system.
The initial phase of RA involves the formation of a pannus in the RA synovium.
This formation consists of monocytes and fibroblasts whose infiltration into the
synovium is facilitated by matrix metalloproteinases produced by the synovial lining
cells. The pannus eventually becomes slightly vascularized and is covered by collagen.
The tissue from which the pannus originates is thought to arise from type B
synoviocytes[2].
Unlike other inflammatory diseases in which non-specific inflammation pervades
the tissue, RA is often characterized by well-structured arrangements of inflammation.
These well-developed ectopic germinal centers are present in the RA synovium, contain
both T and B cells, and represent one of the most striking features of RA[1, 8]. Prior
experiments have examined how T cells function in these germinal centers by comparing
CD4+ T cell clones from the follicles of RA synovium to control CD4+ T cell clones
from the peripheral blood [1]. Specifically, the output of cytokines was measured in
response to fragments of RA synovium that were peripherally injected in a mouse model.
The result was a multi-fold increase in the output of cytokines such as IFN- γ, IL-1β, and
TNF-α in mice with follicular T cells. Interestingly, however, the production of these
cytokines by CD4+ T cells was dependent on the presence of B cells, implicating B cells
in T cell activation[1].
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Furthermore, follicular dendritic cell networks comprise the aforementioned
germinal centers in addition to T and B cells. Studies suggest that in the presence of these
dendritic cell networks, activation-induced cytidine deaminase (AID) is also present[8].
AID is an enzyme required for class switching and hypermutation of immunoglobulins as
they develop an affinity for particular antigens within CD21+ germinal centers. In
addition, levels of AID within T or B cell aggregates correlated directly with anti-CCP
antibody levels in the RA synovial tissue. This finding suggests that AID is associated
with the formation of these antibodies, though a causative role has not been formally
elucidated[8]. This study also corroborates that plasma cells in the germinal centers of
RA patients do produce self-reacting antibodies as detected by anti-CCP antibody levels.
In addition, studies have documented the presence of IL-17 producing T cells
(Th-17 cells) in RA synovial fluid. The quantitative levels of IL-17 were significantly
greater in RA synovial fluid compared to both OA synovial fluid and RA peripheral
blood samples [11]. Since IL-17 is thought to play a role in the inflammatory process
leading to destruction of synovial tissue, bone, and cartilage, the finding that IL-17
producing CD4+ lymphocytes can be isolated from RA synovial tissues is
significant[11]. In addition, observations suggest that IL-27 is involved in the
differentiation of Th-17 cells while IFN- γ plays a role in Th-17 cell polarization,
implicating two other cytokines in the potentiation of IL-17 activity. IL-23 has also been
previously identified in the synovial tissue of RA patients but there is no conclusive
evidence for its role in promoting Th-17 cell proliferation[11].
While CD4+ T lymphocytes have been traditionally considered the primary
source of IL-17, recent studies suggest a role of the innate immune system in producing
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IL-17. Specifically, mast cells in inflamed RA synovial tissue are often triggered by
inflammatory stimuli such as complement, TNF-α, or autoantibodies to produce IL17A[12]. Hueber et. al. also showed not only that mast cells have a likely role in RA
pathogenesis, but also that the role of T lymphocytes in promoting inflammatory arthritis
through mediation of IL-17 might be less than previously thought. In samples of RA
synovial tissue, CD3+ cells (T cell marker) accounted for only 1-8% of IL-17A
producing cells compared to 46-100% colocalization of MCT (mast cell marker) and IL17A production [12]. This finding, however, does not imply that T lymphocytes in
germinal centers do not mediate synovial inflammation through other pathways.
While many individual cytokines and chemokines have been implicated in
downstream pathways that lead to the inflammation and tissue destruction of RA, recent
studies have focused on TNF-α. TNF-α has been described for the past 25 years as a
potential single mediator of RA, with specific attention paid to its presence in the
synovial tissue, role in mediating both pro-inflammatory and anti-inflammatory
cytokines, and even upregulation of TNF receptors in RA[13]. Clinical trials that initially
compared anti-TNF therapy to placebo controls in the mid-1990’s demonstrated a 79%
response rate with anti-TNF therapy as measured by a Paulus 20% response, compared to
an 8% response in placebo controls[13, 14]. A Paulus 20% response is defined as a ≥20%
improvement in at least 4 of the following 6 areas: joint tenderness, joint swelling,
patient’s global assessment of improvement, physician’s global impression of
improvement, morning stiffness, and ESR [15]. Given this clinical benefit, further studies
have focused on the role of TNF-α in the pathogenesis of RA particularly because of its
potential as a therapeutic target. Apart from its well-demonstrated role in mediating

11
inflammation, which in turn is associated with synovial tissue destruction, TNF-α has
been shown to affect angiogenesis, leukocyte trafficking, and hematologic cell lines, all
of which can have systemic effects[13].

Rheumatoid Arthritis: A review of treatment modalities
As demonstrated in the previous sections, the pathogenesis of rheumatoid arthritis
revolves around an aberrant immune response to self-antigens. That immune response
involves extensive cytokine cascades, antibody production, and the local destruction of
bone and tissue due to organized centers of inflammation. As a result, the basic principle
of managing RA revolves around reducing inflammatory mediators. Though the approach
is typically systemic, given the diffuse nature of inflammatory arthritis as well as the
capacity of RA to produce extra-arthrodial disease, therapy has varying levels of
specificity.
Prior to the mid 1990’s, the initial approach to treatment of RA involved steroids
or NSAIDs until disease progression necessitated more potent anti-inflammatory
medications known as DMARDs (disease-modifying anti-rheumatic drugs) [2]. However,
subsequent studies indicated that early initiation of DMARDs in recently diagnosed RA
patients resulted in improved outcomes at multiple endpoints including ESR levels, pain,
and joint mobility [2, 16].
DMARDs have varying mechanisms of action but all mitigate inflammation either
by preventing the proliferation and development of cells involved in inflammation or by
neutralizing the inflammatory mediators produced by such cells. They can be broadly
classified as either synthetic (most commonly methotrexate or leflunomide) or biological
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(most commonly etanercept, adalimumab, or infliximab)[17]. Biological DMARDs are
also referred to as anti-TNFα agents or biologics.
The American College of Rheumatology (ACR) recommendations as of 2008
suggested immediate initiation of methotrexate or leflunomide in all patients diagnosed
with RA regardless of disease duration or severity[18]. Other less common synthetic
DMARDs such as hydroxychloroquine or sulfasalazine were recommended if poor
prognostic factors existed. Poor prognostic features were defined as including “functional
limitations, extra-articular disease, RF positivity +/- anti-CCP positivity, and/or bony
erosions by radiography”[18].
Per the ACR, use of biological DMARDs hinges more on the duration of disease.
In patients with disease duration <6 months, the recommendation is for methotrexate
along with a biologic only in patients with high disease activity. Patients with RA for
longer than 6 months who failed prior methotrexate monotherapy, who have severe
disease, or who have moderate disease but a poor prognosis were candidates for antiTNFα agents[18].
Biologic DMARDs have been shown to be more efficacious when used as
monotherapy compared to both methotrexate and placebo controls[19]. The relative
effect of combination therapy is, however, unclear. Combining methotrexate with an antiTNFα agent resulted in better clinical and functional outcomes when compared to
monotherapy in some studies[17]. Subsequent studies indicate the improved efficacy
conferred by combination therapy might be particularly true for patients who have failed
methotrexate therapy as compared to methotrexate-naïve patients[19]. The current ACR
recommendations acknowledge foremost the effectiveness of biologics, citing that they
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are “efficacious in improving disease activity, function, and quality of life and/or
retarding radiographic progression [of disease] when used alone, in combination with
methotrexate, or in patients for whom treatment with DMARDs other than methotrexate
led to an inadequate response” [18].
Furthermore, apart from lowering serum levels of pro-inflammatory cytokines,
anti-TNFα agents can secondarily help in RA. Infliximab, which is a monoclonal
antibody directed against TNFα, has been shown to lower CRP levels, thereby lowering
levels of downstream complement activation. Complement activation has been previously
linked to the pathogenesis of RA in animal models[20].
When considering adverse events associated with anti-TNF therapy, the most
common concern is infection[21]. Infliximab, in particular, has been associated with a
higher incidence of severe infection[19]. Multiple studies have raised the possibility of
etanercept being linked to a higher incidence of malignancy, including lymphoma and
skin cancer. However, no statistically significant association exists, including in a metaanalysis of more than 3300 patients [19, 21, 22]. There is limited evidence from clinical
trials suggesting that newer biologics such as abatacept and rituximab might have more
favorable safety profiles, though this is far from conclusive[21].

Peri-Implant Osteolysis
Despite the reviewed understanding of the natural history of RA as well as
management strategies that target its immunologic pathophysiology, the disease and its
optimal management have not been fully characterized in patients with arthroplasties.
When joint destruction related to the severity of disease necessitates a prosthetic implant,
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RA patients not only have to deal with their underlying inflammatory arthritis but also the
body’s response to an implant.
Orthopedic interventions are relatively common in RA patients. Of 183 RA
patients who were followed for 16-20 years in a prospective study, 58% underwent some
form of orthopedic surgery and 24% had a joint replacement. Arthroplasties of all major
joints were noted with hips and knees being the most common, but non-weight bearing
joints such as elbows, shoulders, wrists, and fingers together represented 36% of the
arthroplasties performed [23]. A prosthetic joint has multiple components. It typically
consists of two metal stems that are inserted into each of the two bones forming a joint.
These metal stems are often cemented in place and are joined with metal axles, using
polyethylene bushings as a lubricating surface.
From a biomechanical perspective, the polyethylene bushings absorb great
amounts of impact and are vulnerable to deterioration over time. In elbow arthroplasties,
for example, Lee et. al. found that the polyethylene bushings had to be replaced at an
average of 7.9 years[24]. Goldberg et. al. also found that the ulnar and humeral
polyethylene bushings found in total elbow arthroplasties are the weakest components of
the device[25]. As the implant is in place for an extended period of time, the
polyethylene surface is slowly deformed leading to loss of microscopic pieces of
polyethylene into the tissue surrounding the arthroplasty. If enough of the polyethylene
lubricating surface is deformed, the metal components of the implant eventually articulate
causing pieces of metal debris to also spread into the peri-prosthetic tissue.
Numerous studies have demonstrated that both polyethylene and titanium metal
particles in the peri-prosthetic tissue are linked to osteolysis, or loss of peri-implant bone,
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which in turn causes aseptic loosening of the arthroplasty. Initial models suggested three
potential mechanisms for wear debris-induced inflammation that bring about destruction
of bone[26].
First, macrophages activated by the phagocytosis of particulate debris have been
shown to generate nitric oxide. Such free radicals in turn worsen inflammation in the
joint tissue and facilitate the activation of osteoclastic differentiation and enzymatic
activation[26]. Initial studies indicated that titanium alloy had the largest effect in
stimulating nitrite production in a mouse model, likely through upregulation of inducible
nitric oxide synthase. Pure titanium metal and polymethylmethacrylate showed slightly
lower levels of nitrite production[27].
Second, Wang et. al. demonstrated that exposure of bone marrow cells to foreign
body wear debris over time causes a decrease in mesenchymal stem cells’ (MSC) ability
to differentiate into osteoblasts. The mechanism through which titanium particles in
particular suppress osteoblastic differentiation appears to hinge on suppression of the
BSP gene[26]. Third, titanium particles have also been linked to promoting apoptosis of
MSC’s. Mechanisms of reduced MSC viability include p53-mediated apoptosis and
activation of death receptors by TNFα[26].
While many of the previously noted studies suggest a significant role for titanium
metal in bringing about osteolysis, polyethylene has been extensively linked to aseptic
loosening as well. Numerous studies suggest that the tissue reaction to polyethylene
debris depends on the size and manufacturing properties such as cross-linking [28]. The
mechanism of polyethylene-induced osteolysis is postulated to be similar to titanium
metal particles in that macrophages activated by the phagocytosis of particles bring about
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a release of pro-inflammatory cytokines, including TNFα. These cytokines in turn
upregulate matrix metalloproteinases as well as RANK and RANK ligand, which directly
increase osteoclastic differentiation and proliferation leading to osteolysis[28, 29]. At the
same time, bone formation is uncoupled from resorption such that apoptotic pathways
preferentially promote the survival of osteoclasts and death of immature osteoblasts,
largely through the action of TNFα [28, 30, 31]. The dose-dependent preference of
apoptotic pathways for immature over mature osteoblast lineages has been specifically
demonstrated in vitro[31].
Although the role of the innate immune system in responding to foreign body
wear debris has been well described, the role of the adaptive immune system is less
certain. Willert et. al. described the presence of a lymphocytic infiltrate in the periprosthetic tissue of patients with metal-on-metal hip implants that had resulted in aseptic
loosening[32]. Goldberg et. al. examined the peri-articular tissue taken during revision of
a total elbow arthroplasty for aseptic loosening due to osteolysis. While this study noted a
robust giant cell and histiocytic response, 69% showed a minimal lymphocytic response
and 12% showed a significant lymphocytic response[25]. Hallab et. al. showed a Th1
lymphocytic response was detected in response to a metal challenge test in patients with
total hip arthroplasties. An increase in IFN- γ, which is released by Th1 lymphocytes and
is associated with osteoclast activity, supports this claim. The emergence of a subset of T
lymphocytes indicates a level of specificity consistent with an adaptive immune response
to metallic debris[33]. While some studies have also postulated how RANKL expression
on the surface of T cells is sensitive to TNFα and might also promote osteolysis, other
studies have shown no osteolysis in lymphocyte-deficient mice[30, 34].
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Purpose of Present Study
Peri-implant osteolysis and associated loss of fixation is the major reason total
joint replacements fail. The progressive loss of bone adjacent to the implant has been
attributed to a granulomatous inflammatory reaction induced by particulate implant wear
debris at the bone-implant interface [35]. Patients frequently exhibit dramatic differences
in the rate of peri-implant bone loss, and it is unclear whether this reflects differences in
the properties or amount of wear debris, differential patterns of biomechanical failure, or
differences in individual host immune response.
This distinction regarding the underlying mechanism driving aseptic loosening is
particularly critical in patients who are already susceptible to an overblown inflammatory
response, as occurs in RA. RA patients with arthroplasties respond to both the baseline
inflammatory properties of particulate debris, and the organized inflammation and joint
destruction characteristic of this inflammatory arthritis.
Studies by Caplan and coworkers noted that coal miners with RA who were
exposed to silica containing coal dust were uniquely prone to the development of large
pulmonary granulomas (“Caplan’s nodules”) [36]. They speculated that this differential
response to an inorganic particulate reflected an intrinsic alteration in immunoregulation
among RA patients. Similarly, RA patients may exhibit a unique immune response to the
inorganic wear particles generated by prosthetic implants, which might lead to different
failure mechanisms compared with non-RA patients.
Kaufman et. al. reported on a series of patients undergoing revision surgery for
aseptic failure after TEA [37].They did not note a difference in the cellular features of the
peri-implant tissue reaction in patients with or without inflammatory arthritis. More
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recently, Goldberg et. al. evaluated the tissue reaction accompanying failed, semiconstrained, Coonrad-Morrey elbow implants at primary revision in sixteen patients, nine
of whom had inflammatory arthritis [25]. Similarly, the peri-prosthetic tissue showed no
evidence of a differing cellular reaction on the basis of underlying diagnosis. In contrast,
Goldring et. al. found that among a similar group of patients, lymphoplasmacytic
inflammation was found exclusively in RA patients [38]. Factors responsible for these
contradictory findings could include differences in the composition and types of devices,
differences in patient populations, and differences in treatment.

Aims of Study
The present study was undertaken to compare cellular features of the peri-implant tissue
response among patients with and without RA undergoing revision of a TEA due to
aseptic loosening, and to ascertain the relationship with underlying disease, patterns of
gross device wear, and the amount and type of particulate debris.

19
Patients and Methods
Identification of Patients
Surgical specimens from all primary TEA revisions performed between 1996 and 2008
for aseptic loosening were identified from the database of the Department of Pathology
and Laboratory Medicine at the Hospital for Special Surgery (HSS). Given that the elbow
is a non-weight bearing joint, this population is not predominated by degenerative joint
disease and is, therefore, enriched for RA patients. Implant components corresponding to
the identified cases were recovered through the Implant Retrieval Registry in the
Hospital’s Department of Biomechanics. The patients’ primary diagnosis, gender, race,
age at primary TEA, age at revision TEA, pre-revision medical treatment, pre-revision
flexion-extension range of motion, dominant hand, as well as height and weight at the
time of revision were obtained from medical records. Non-RA patients include noninflammatory arthritis patients with a history of OA or trauma. RA patients were labeled
treated or untreated based on pre-operative usage of a TNF-inhibitor. When stratifying
patients on this basis, those in whom this data was unavailable were excluded from
analysis. Duration of implantation was defined as the number of years between the
original TEA and primary revision TEA. A short duration of implantation was <4 yrs; a
long duration of implantation was ≥ 4 yrs. HSS Institutional Review Board approval was
obtained for this study.

Device Evaluation
As available, the retrieved humeral and ulnar components, humeral polyethylene
bushing (Fig. 1A), and axle were evaluated for evidence of wear and surface damage.
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Due to the limited number of metal components (Fig. 1B), no information was collected
on metal loss.
A previously developed subjective scoring method was used to assess seven
modes of polyethylene damage [39]. Of the seven modes, conformational change, due
either to deformation or material loss, was considered the most accurate and functionally
relevant metric of biomechanical damage. Grades of none, mild, moderate or severe
corresponded with 0, <10%, 10-50%, and >50% of the articulating surface area being
visually thinner than the non-articulating surface. However, this scoring system was
insufficient to estimate the extent of wear in instances of penetrating focal damage. Focal
wear was measured separately as the proportion of thinning in a localized area between
the inner and outer bushing diameters compared to a non-deformed region. Focal wear
was graded as none, mild, moderate, or severe corresponding to the diameter being 0,
<10%, 10-50%, and >50% thinner compared with the non-deformed surface. A device’s
final grade was the highest qualifying score on the basis of either surface area damaged
or focal wear.
All grading was done under a stereomicroscope while blinded to both the
underlying diagnosis and tissue histology. Grading was performed independently by two
readers (AV and DC). Differences were resolved by consensus.

Histopathology
Hematoxylin and eosin stained samples of peri-prosthetic tissue were evaluated for the
type and size of particulate material, as well as the presence, type, location, and intensity
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of inflammatory infiltrates. This analysis is based on a modification of a similar analysis
published elsewhere [40].
Polyethylene debris particles were classified as either small (<500µm) or large
(≥500 µm) based on the largest dimension (Fig. 1C). Metal particles were not stratified
by size, as they were uniformly small particles (~10µm) with little heterogeneity on the
basis of visual identification. The distribution of polyethylene debris was defined as low
prevalence or high prevalence. Low prevalence was defined as wear particles seen in
≤50% of the area of at least 2 histologic fields viewed at 10x magnification. For metallic
debris, which was less common, low prevalence was defined as particles seen in ≤10% of
the area of at least 2 histologic fields viewed at 10x magnification.
In describing the peri-prosthetic tissue reaction, monocytes and giant cells were
defined as low prevalence if they comprised ≤ 50% of the cellular infiltrate on two
separate 10x fields, and high prevalence if they comprised >50%. A lymphocytic
aggregate was defined as a group of ≥10 lymphocytes visualized on a 5x field.
Perivascular infiltrates surrounded a discernable vascular structure (Fig. 1D). Focal
interstitial infiltrates were defined as aggregates of lymphocytes in the absence of a
discernable vascular structure (Fig. 1E). Sheet-like aggregates were defined as a diffuse
interstitial pattern of lymphocytic infiltrates throughout the entire tissue section (Fig. 1F).
Focal interstitial and sheet-like aggregates represent two degrees of intensity of
interstitial lymphocytic inflammation. When evaluating plasma cells within lymphocytic
aggregates, low prevalence of plasma cells was defined as comprising ≤ 10% of the
lymphocytic aggregate, and high prevalence >10% of the aggregate in two separate 10x
fields.
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To confirm that our histologic identification of cell types was correct,
immunohistochemistry was performed on tissue from a representative subset of cases. Tand B-lymphocytes were identified by using anti-CD3 and anti-CD20 antibodies,
respectively, and plasma cells by using anti-Kappa and anti-Lambda antibodies.

A

B

C

D

E

F

Figure 1. A.) Humeral polyethylene bushing showing focal, severe conformational change (thin arrow).
Moderate conformational change present on the opposite end of bushing (thick arrow). B.) Moderate
metal loss on the proximal portion of the humeral stem (white arrow). C.) Small particulate polyethylene
of high prevalence shown in polarized light at 10x. D.) Perivascular lymphocytic inflammation (40x) E.)
Interstitial lymphocytic inflammation (40x) with visible plasma cells (thin arrow). Metallic debris being
phagocytosed by foreign body giant cells (thick arrow). F.) Sheet-like lymphocytic infiltration with
widespread plasma cells (thick arrow) at 40x. Metallic debris present across entire field (white star).
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Osteolysis
Available anterior-posterior (AP) and lateral pre-operative radiographs were evaluated
for the presence of osteolysis based on a previously used scoring system [25]. The
humeral and ulnar stems of the prosthetic were divided into 4 zones each and examined
for the presence of radiolucencies at both the cement-prosthesis and cement-bone
interface.

Statistical Analysis
Fisher’s Exact test was used to compare all categorical variables. Sample size made this a
more high fidelity test than Chi-squared. T-tests were performed on continuous data. A
kappa analysis was performed to establish inter- and intra-rater reliability of the
qualitative histologic scoring.

Contributions to Present Study
Primary responsibility for all data collection, compilation, and analysis was held
by Anant Vasudevan. Dr. Lisa Mandl was the principal investigator who oversaw and
contributed to all progress in data collection, analysis, and communication of results.
Anant Vasudevan, Dr. Mandl, and Dr. Goldring shared responsibility for study design,
analysis of data, and interpretation of results. In examining devices, Dan Chen and Anant
Vasudevan shared equal responsibility in grading all aspects of implant wear. Dr. Wright
aided in the design of parameters through which to assess devices and provided opinions
as needed. In examining histology samples, Dr. DiCarlo provided expert qualitative
impressions of both particle burden and the extent of the inflammatory tissue reaction to
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wear debris. Anant Vasudevan and Dr. DiCarlo examined all histopathology slides and
collected all data together. Immunohistochemical analysis of histology samples was
performed commercially. The chart review was performed by Anant Vasudevan. In
assessing osteolysis, Anant Vasudevan helped assemble the parameters for evaluating
radiographs, and Dr. Figgie, an orthopedic surgeon, provided expert reads of films.
Statistical analysis was performed by Anant Vasudevan except the kappa analysis for
inter/intra-rater reliability, which was done by Dr. Stephen Lyman of the HSS
Biostatistical Core. All authors contributed to revising the Methods, Results, and
Discussion sections of this manuscript.
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Results
Profile of Patients
Of 88 cases, 11 were excluded because of infection. Of the remaining 77 cases, 39 had
inadequate tissue for review. Complete medical records were available in 36 of the
remaining 38 patients; two had only the operative record and partial medical records.
Twenty-five of the 38 patients had RA (66%), 7 had OA (18%), and 6 had a
history of traumatic elbow injury without underlying inflammatory arthritis (16%). Of the
25 RA patients, 24 had pre-operative medication data. Ten RA patients were on a TNF
inhibitor pre-operatively (etanercept in all cases). The remaining 14 RA patients were not
on a TNF inhibitor pre-operatively. None of the non-RA patients were pre-operatively on
a TNF inhibitor. 4 patients (3 RA and 1 non-RA) underwent revision surgery prior to
FDA approval of etanercept.
Of all RA patients, 91% were Caucasian, 84% were women, and 95% were righthanded compared to 100%, 87%, and 100% respectively in non-RA patients. The right
elbow was the operative site in just under half of both groups. Thirteen percent of RA
patients and 33% of non-RA patients had a BMI >30 (p = 0.19). The average preoperative range of motion was 112° (0 to 210°) for RA patients and 109° (60 to 130°) for
non-RA patients (p = 0.85). RA patients were younger at the time of original implant
surgery (p=0.0003). The average duration of implantation was 8.9 yrs for all RA patients
and 5.3 yrs for non-RA patients (p = 0.06) (Table 1).
Untreated RA patients had a longer time to primary revision than treated RA
patients (10.9 vs. 5.8 yrs, p = 0.04) or non-RA patients (10.9 vs. 5.3 yrs, p = 0.01). There
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was no difference in the duration of implantation between non-RA patients and treated
RA patients (5.8 vs. 5.3 yrs; p = 0.77).
RA: 25
Female
Race
Caucasian
Black
Asian

84%
(N = 23)
91.3%
4.3%
4.3%

Non-RA: 13 (7OA,
6 Trauma)
87%
(N = 13)
100%
0%
0%

P-value
1.0
1.0

Avg. Age at Original 50.8 ± 12.3 yrs (N = 24)
Implant

66.1 ± 8.1 yrs

0.0003

Avg. Age at First
Revision

58.3 ± 15.0 yrs

71.4 ± 6.8 yrs

0.005

8.9 ± 5.8 yrs

5.3 ± 4.3 yrs

0.06

112.2° (N = 20)

108.9° (N = 8)

0.85

Index Elbow

44% Right Elbow

46% Right Elbow

1.0

Dominant Hand

95% right-handed
(N = 19)

100% right-handed
(N = 13)

1.0

BMI (< 30 vs. ≥ 30):
18.5 – 24.9
25.0 – 29.9
≥ 30.0

(N = 24)
13
8
3

(N = 12)
5
3
4

0.19

DMARDS:
Etanercept
+ Methotrexate
+ Imuran

(N = 24)
10
3
1

(N = 12)
0
-

3
6

4
0

Duration of
Implantation
Range of Motion
(Flex-Ext)

Bisphosphonates
Prednisone

0.40
0.28

Table 1. Descriptive statistics on 38 TEA patients. 25 RA and 13 non-RA patients used for each variable unless otherwise indicated.
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Biomechanical Wear
Of the 38 patients in this study, 24 had semi-constrained retrieved implants
available for analysis. Twelve of the implants were Osteonics Linked Semiconstrained
replacements manufactured by Osteonics, 7 were Coonrad-Morrey implants
manufactured by Zimmer, 2 were Solar devices manufactured by Stryker, 2 were Triaxial
prostheses manufactured by Johnson and Johnson, and 1 was a custom device. All
devices had humeral polyethylene bushings. Metal components were available for 15, of
which 3 contained both humeral and ulnar components, 7 contained only the humeral
component, and 5 contained only the ulnar component. Five of the axle-containing
devices had no axle available for analysis. All metal components were titanium.
Conformational changes in the 24 humeral polyethylene bushings were mild in
10, moderate in 3, and severe in 11. Moderate changes were qualitatively much closer to
severe than mild, so moderate and severe categories were grouped for statistical analysis.
No difference in severity of conformational changes were noted between CoonradMorrey implants and other designs (p = 0.08). More severe conformational change was
associated with a longer duration of implantation of >4 years (p = 0.01). Conformational
change showed no association with underlying diagnosis (RA vs. non-RA, p = 1.0), or
with use of TNF inhibitors (p = 1.0) (Fig. 2A), regardless of whether the 3 instances of
moderate changes were excluded.
Histopathologic Analysis
a) Particulate Debris
Polyethylene and metal particles were observed in varying quantities in the periprosthetic tissue reaction. Increased polyethylene particle prevalence (p = 0.01) and size
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(p = 0.005) and increased metal particle prevalence (p=0.05) were all associated with
more severe conformational change (Fig. 2B-D).
Conformational Change of Polyethylene Bushing

p = 1.0

Pct of Patients

100%

p = 1.0

p = 1.0

A

Severe

80%
60%

Mild

40%
20%
0%
Non-RA

Treated RA

Untreated RA

N = 24

Patient Group

Pct of Patients

Prevalence of Polyethylene Particles in Tissue

p = 0.01

100%
80%

B

High
Prevalence

60%
40%

Low
Prevalence

20%
0%
Mild Conformational
Change

Severe Conformational
Change

N = 24

Pct of Patients

Size of Polyethylene Particles in Tissue
100%

p = 0.005

Large
Polyethylene
Particles

80%
60%
40%

Small
Polyethylene
Particles

20%
0%
Mild Conformational
Change

Severe Conformational
Change

Prevalence of Metal Particles in Tissue

Pct of Patients

C

100%

p = 0.05

80%

N = 24

D
High
Prevalence

60%
40%

Low
Prevalence

20%
0%
Mild Conformational
Change

Severe Conformational
Change

N = 24

Figure 2. A.) Degree of conformational change, adjusted for cases of focally
severe damage, did not vary with underlying diagnosis or use of anti-TNF
therapy. Severe conformational change in the humeral polyethylene bushing
is associated with higher polyethylene particle prevalence (B), larger
polyethylene particle size (C), and a trend towards higher metal particle
prevalence (D).
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Increased polyethylene particle prevalence (p = 0.06) and increased polyethylene
particle size (p = 0.03) were associated with duration of implantation > 4 yrs. Metal
particle prevalence was not associated with duration of implantation (p = 0.15).
No difference was found in the prevalence or size of polyethylene particles among
non-RA patients, treated RA patients, or untreated RA patients (p ≥ 0.65 for all
comparisons) (Fig. 3A-B). Similarly, no difference existed in the prevalence of metal
particles among these three groups (p ≥ 0.68) (Fig. 3C).
Prevalence of Polyethylene Particles in Tissue

Pct of Patients

100%

p = 0.65

p = 0.70
p = 0.67

A

High
Prevalence

80%
60%

Low
Prevalence

40%
20%
0%
Non-RA

Treated RA

Untreated RA

N = 37

Patient Group

Size of Polyethylene Particles in Tissue

p = 1.0

Pct of Patients

100%

p = 1.0

p = 0.70

B

Large
Polyethylene
Particles

80%
60%

Small
Polyethylene
Particles

40%
20%
0%
Non-RA

Treated RA

Untreated RA

Patient Group

Prevalence of Metal Particles in Tissue

Pct of Patients

100%

p = 1.0

p = 1.0

N = 37

C

p = 0.68
High
Prevalence

80%
60%
40%

Low
Prevalence

20%
0%
Non-RA

Treated RA
Patient Group

Untreated RA

N = 37

Figure 3. Prevalence of polyethylene particles (A), size of polyethylene
particles (B), and prevalence of metal particles (C) did not vary with
underlying diagnosis or anti-TNF therapy.
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b) Tissue Reaction:
A higher prevalence of foreign body giant cells was associated with a higher
prevalence of polyethylene particles (p < 0.001), larger polyethylene particles (p =
0.004), and higher prevalence of metal particles (p = 0.04). There were no significant
differences in the prevalence of foreign body giant cells (p = 0.73) between non-RA
patients and RA patients. This finding did not change when RA patients were stratified
by use of anti-TNF therapy (p = 1.0).
No association was found between the prevalence of monocytes and the
prevalence of polyethylene particles (p = 0.24), size of polyethylene particles (p = 0.25),
or prevalence of metal particles (p = 1.0). There were no significant differences in the
prevalence of monocytes (p = 0.12) between non-RA patients and RA patients. This
finding did not change when RA patients were stratified by use of anti-TNF therapy (p =
1.0).
The presence of any lymphocytic aggregates was associated with lower metal
particle prevalence (p = 0.005) but not with polyethylene particle prevalence (p = 0.14) or
size (p = 0.32). An increased plasma cell prevalence within lymphocytic aggregates was
associated with widespread metal particles (p = 0.049) but was not significantly
associated with polyethylene prevalence (p = 0.36) or size (p = 0.40).
c) Extent of Inflammatory Reaction:
In the presence of any type of wear debris, untreated RA patients showed an
interstitial pattern of lymphocytic aggregation as opposed to the predominantly
perivascular pattern seen in non-RA patients (p = 0.04). Treated RA patients showed a
mixed pattern of perivascular and interstitial lymphocytic infiltrates intermediate between
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non-RA patients and untreated RA patients (Fig. 4A). 50% of untreated RA patients also
showed a sheet-like intensity of lymphocytic infiltrates compared to none of the non-RA
patients (p = 0.09). Treated RA patients showed a mixed intensity of lymphocytic
infiltrates with 22% being diffuse, sheet-like infiltrates.
A similar pattern of lymphocytic infiltration was seen when considering only
patients with small or few wear particles of any type. The majority of these patients had
≤10% plasma cells in the lymphocytic aggregates, with no significant difference when
comparing underlying diagnosis, treatment, or particle composition.
Among patients with a high prevalence of polyethylene debris, including small
and large particles, all untreated RA patients showed lymphocytic infiltrates with an
interstitial or diffuse sheet-like appearance, associated with a high prevalence of plasma
cells. This pattern was present in only half of treated RA patients. Only one non-RA
patient exhibited this pattern of polyethylene debris, and in this patient the lymphocytic
aggregates were perivascular and associated with a low prevalence of plasma cells (p
=0.33) (Fig. 4B). The cellular patterns were similar in tissue sections containing
predominantly large non-phagocytosable polyethylene particles (Fig. 4C). Again, all
untreated RA patients had a high prevalence of plasma cells in lymphocytic infiltrates
compared with none of the non-RA patients (p = 0.07). Only one-third of treated RA
patients exhibited this pattern.
In the presence of a high prevalence of metal debris, untreated RA patients had
exclusively lymphocytic aggregates with an interstitial or sheet-like appearance that were
associated with a high plasma cell prevalence (Fig. 4D). Unlike the histologic findings
associated with polyethylene, 40% of the non-RA patients had lymphocytic aggregates
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with high plasma cell prevalence; however, unlike the RA patients, the plasma cells were
associated with focal interstitial or perivascular lymphocytic aggregates. Treated RA
patients had a prevalence of plasma cells similar to the non-RA patients (p = 1.0).
Location of Lymphocytic Aggregates

Pct of Patients

100%

A

p = 0.04
p = 0.27

p = 0.60

Sheet-like

80%
60%

Focal
Interstitial

40%

Perivascular

20%
0%
Non-RA

Treated RA
Patient Group

Untreated RA

N = 24

High Prevalence of Polyethylene Particles

Pct of Patients

100%

p = 0.33
p = 1.0

p = 1.0

80%
60%
40%
20%
0%
Non-RA

Treated RA

Untreated RA

Patient Group

Large Particulate Polyethylene

p = 1.0

Pct of Patients

100%

p = 0.07

p = 0.14

80%
60%
40%
20%
0%
Non-RA

Treated RA

Untreated RA

Patient Group

High Prevalence of Metal Particles

Pct of Patients

100%

p = 1.0

p = 0.33
p = 0.17

80%
60%
40%
20%
0%
Non-RA

Treated RA
Patient Group

Untreated RA

B

High Plasma
Cell
Prevalence in
Lymphocytic
Aggregates
Low Plasma
Cell
Prevalence in
Lymphocytic
Aggregates

N=5

C
High Plasma
Cell
Prevalence in
Lymphocytic
Aggregates
Low Plasma
Cell
Prevalence in
Lymphocytic
Aggregates
Aggregates

N=9

D
High Plasma
Cell
Prevalence in
Lymphocytic
Aggregates
Low Plasma
Cell
Prevalence in
Lymphocytic
Aggregates

N = 11

Figure 4. A.) Untreated RA patients show predominantly interstitial and sheet-like lymphocytic aggregates in response to foreign body
wear debris. This is significantly different from non-RA patients. Treated RA patients show a mix of perivascular and interstitial
aggregates in between non-RA and untreated RA patients. In patients with a high prevalence of polyethylene (B) or large particulate
polyethylene (C), non-RA patients show exclusively a low plasma cell prevalence within lymphocytic aggregates. Untreated RA
patients show exclusively a high plasma cell prevalence. D.) In patients with a high prevalence of metal particles, untreated RA
patients show exclusively high plasma cell prevalence within lymphocytic aggregates. ≥ 50% of treated RA patients and non-RA
patients showed a low plasma cell prevalence.
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d) Immunohistochemistry
A representative convenience sample of peri-prosthetic tissue from 2 non-RA
cases, 3 treated RA cases, and 3 untreated RA cases was selected for
immunohistochemical staining. T- and B-lymphocytes were identified by using anti-CD3
and anti-CD20 antibodies, respectively, and plasma cells by using anti-Kappa and antiLambda antibodies. Repeat evaluation for the presence, type, location, and intensity of
inflammatory infiltrates using cells identified via immunohistochemistry showed
identical results to the reviews based on visual identification of cell types.

Radiographic Analysis
Of the 38 patients in this study, 18 had lateral radiographs and 17 of these 18 had AP
radiographs available for review. These 18 patients included 5 non-RA, 3 treated RA,
and 10 untreated RA patients.
At the cement-prosthesis interface, none of the RA patients had radiolucencies,
regardless of treatment. One of five non-RA patients showed radiolucencies. At the
cement-bone interface, 9 of 18 patients showed radiolucencies, including 2 non-RA, 2
treated RA and 5 untreated RA patients. There was no association between the presence
of radiolucencies and treatment with etanercept, among RA patients (p = 1.0). Similarly,
there was no difference in the presence of radiolucencies between non-RA and RA
patients (p = 1.0).
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Inter/Intra-rater Reliability of Statistical Methods
7 of 24 devices and 10 of 38 slides were randomly selected for kappa analysis.
The inter-rater kappa values were 0.84, 1.0, 0.58, 0.62, 0.29, and 1.0, and the intra-rater
analysis values were 0.63, 1.0, 0.74, 0.74, 0.55, and 1.0 for location of lymphocytic
infiltrate, plasma cell prevalence, polyethylene prevalence, polyethylene size, metal
prevalence, and deformation of the humeral polyethylene bushing respectively.
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Discussion
Our results show that conformational change in the polyethylene bushing is
strongly associated with large particulate polyethylene debris and a high prevalence of
metal and polyethylene particles, confirming that conformational change in the bushing is
due to loss of material, not just deformation. Of note, no difference was found between
RA and non-RA patients in terms of the severity of device deformation, the composition
or magnitude of wear debris, or the average pre-operative range of motion, suggesting
that differences in cellular and tissue reactions cannot be attributed to these factors. The
only positive association with less conformational change and wear debris was having a
primary TEA revised <4 years after implantation, regardless of underlying diagnosis.
We found an increase in the intensity of lymphocytic aggregates among untreated
RA patients, which correlated with the presence of metal and polyethylene particles.
This finding suggests activation of the adaptive immune system in these patients.
Analysis of the pattern of prosthetic wear revealed that the ulnar and humeral
polyethylene bushings exhibited extensive wear and fragmentation, including metal
particle formation related to unintended metal-on-metal wear. Previous studies reported
the presence of an inflammatory cell infiltrate and multinucleated giant cells with regions
of fibrosis as well as focal necrosis associated with extra- and intracellular metallic and
polymeric particles within histiocytes [25, 41]. Only a minimal lymphocytic reaction was
found in most cases, and no difference in cellular characteristics was reported between
patients with or without inflammatory arthritis. Our study suggests that while no increase
occurred in the presence of lymphoplasmacytic infiltrates in patients with inflammatory
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arthritis, the degree of plasma cell infiltrates was significantly increased among those
with diffuse lymphocytic aggregates.
The presence of plasma cells associated with metal wear debris is a characteristic
histologic feature in patients undergoing revision surgery after metal-on-metal hip
resurfacing [42, 43]. Diffuse aggregates of lymphocytes and plasma cells are associated
with regions of tissue necrosis and extensive fibrin deposition. The reaction is thought to
represent a hypersensitivity to the metal wear products. These findings differ
substantially from those in our series and other TEA series [25, 41], and may represent a
distinct clinical entity in a weight bearing joint. However, most of the patients on antiTNF therapy in our study demonstrated a similar, high prevalence of plasma cells only in
tissue sites with high metal debris prevalence, suggesting that metal debris may initiate
the plasmacytic response. The presence of lymphocytic aggregates, however, was
significantly associated with lower metal particle prevalence. This suggests that while
metal might specifically bring about a plasmacytic response, polyethylene may be driving
the broader lymphocytic response in these patients. Though no definitive correlation
exists between polyethylene and a robust lymphocytic response, prior studies have
demonstrated lymphocytic infiltrates in response to wear debris even from arthroplasties
that are not exclusively metal-on-metal [25]. Another possibility is that metal particles in
the nanometer range, which have been previously described particularly in metal-onmetal implants and are not counted through visual identification, could cause an
underestimation of the true metal particle burden and its contribution to a lymphocytic
response [44].
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Fujishiro et al. recently reviewed a large series of patients undergoing revision
surgery after total hip replacement for non-metal-on-metal implants [45]. Their series
was restricted to patients without known inflammatory arthritis, and included patients
undergoing revision surgery for septic joints. They noted lymphocytic infiltrates in half
of the patients with aseptic loosening, 62% of whom demonstrated a diffuse pattern of
lymphocytic infiltration. They noted that the diffuse pattern was most commonly
associated with regions of metal wear accumulation. Only 7% of aseptic cases had
plasma cells associated with the lymphocytic aggregates. Their detection of plasma cells
in a low number of non-RA patients is similar to our findings, and contrasts with the high
prevalence of these cells in our RA patients.
The present study’s findings confirm earlier observations in RA patients
undergoing revision surgery for failed total knee replacement [38]. Although we detected
the presence of lymphocytic infiltrates in the tissue from both RA and non-RA patients,
the pattern of tissue distribution and extent of the infiltrates differed substantially
between the two patient subsets. The infiltrates in non-RA patients were focal with
predominantly perivascular localization and few plasma cells. In contrast, in RA patients
the infiltrates exhibited both a perivascular and interstitial pattern of distribution and were
often organized into sheet-like infiltrates with a high proportion of plasma cells. High
polyethylene particle prevalence and large polyethylene particle size were associated with
a high plasma cell prevalence within lymphocytic aggregates in RA patients. In contrast,
no non-RA patients with many or large polyethylene particles in the peri-implant tissue
had lymphocytic aggregates with a high plasma cell prevalence. The prevalence of
plasma cells in treated RA patients fell between these two groups, suggesting that the
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reduction in systemic and tissue inflammation associated with anti-TNF therapy results in
attenuation of the pattern of cellular responses observed in RA patients.
Our results provide evidence that patients with RA exhibit a differential cellular
reaction to inorganic metallic and polyethylene debris compared to patients without RA.
The tissue reaction in the non-RA patients exhibited features of a non-immune
granuloma. Lymphocytic infiltrates were scattered within the tissue and limited primarily
to a perivascular location. In the untreated RA patients, the presence of more generalized
lymphocytic infiltrates containing abundant plasma cells are indicative of participation of
cellular components of both the innate and adaptive immune system, a feature
characteristic of an “immune granuloma.” These findings recapitulate the observations of
Caplan and coworkers who described the presence of atypical pulmonary nodules in a
series of coal miners [46]. Histopathologic analysis of those nodules revealed the
presence of immune granulomas with extensive lymphocytic infiltration with T and B
cells. Importantly, these lesions were absent in miners without RA or in RA patients
without exposure to coal dust, leading to the hypothesis that these findings reflected an
aberrant immune response to the inorganic components of the coal dust in the RA
patients.
The nature of the underlying immunologic mechanisms by which inorganic
particles initiate an inflammatory reaction with cellular features of an immune
granulomatous response remains speculative. Importantly, this reaction in both periimplant tissues and “Caplan’s nodules” develops in the absence of articular cartilage.
Cartilage matrix components have been implicated as potential immunogens in the
pathogenesis of RA synovitis; our observations provide evidence that cartilage is not
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playing a role in the immune response [47]. The association of anti-TNF therapy with
diminished cellular features of the tissue reaction parallels its known effects in reducing
inflammatory cell infiltrates in RA synovium [48].
In addition, there was no difference in the presence of radiolucencies between
patients treated and not treated with etanercept. While limited by a small sample size and
the unavailability of three-dimensional imaging, these findings are consistent with other
studies, which have not found anti-TNF medications to be protective against osteolysis
[49].
Our data show a trend towards the TEA lasting longer in RA patients compared
with non-RA patients. This could be due to lower demands placed on the joint
replacement by RA patients. However, treated RA patients show a length of implantation
similar to non-RA patients and shorter than untreated RA patients. Users of TNFinhibitors may have had better-controlled disease, enabling them to resume normal
function with higher forces across the joint, accelerating prosthesis loosening.
Finally, the inter-rater and intra-rater reliability testing of important qualitative
variables in our study helps support the integrity of our dataset. The acceptable kappa
values provide evidence that our scoring methods are reproducible, accurate, and
unaffected by the personal bias of a scorer directly involved in our study. Having this
confidence is critical in evaluating the raw data presented in this paper, especially given
the subjective nature of determining the extent of device wear and recognizing both wear
debris particles and immunologic cell morphology in peri-prosthetic tissue. However,
strict, detailed, and previously vetted criteria were used as the basis for all qualitative
evaluation, and the dependability of the results was confirmed by independent scorers.
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In summary, we provide evidence that patients with RA exhibit a differential
cellular response to prosthetic wear debris compared with non-RA patients, and that this
reaction is mitigated by the use of anti-TNF inhibitors. The immune tissue reaction is
similar to that observed in RA patients exposed to silica, another inorganic particle, and
specifically consistent with earlier findings of Goldring et. al [38]. Of note, this reaction
develops in the absence of articular cartilage, which has been implicated in the
immunopathogenesis of RA synovitis [47, 50]. These results provide evidence of a
pathogenic activation of the adaptive immune response in RA and could have
implications for the treatment of peri-implant osteolysis.

Limitations
Limitations of our study include the small sample size and retrospective data
collection. Data were collected cross-sectionally from the time of revision surgery,
making it impossible to assign causation. Histopathologic analysis was also limited by
the number of available slides. Etanercept was FDA approved in 1998. Patients with
more severe RA operated on after 1998 may have been more likely to receive a TNF
inhibitor, a potential systematic bias. However, the fact that anti-TNF therapy was not
readily available until early 1999 prevented any confounding by indication for the first
three years of our cohort. Inter-rater and intra-rater reliability testing was performed for
all key variables in this study except those associated with evaluation of radiographs. The
previously described scoring system by Goldberg et. al. was specifically designed for a
TEA and explicit in terms of device evaluation. As a result, only one read of films by an
expert orthopedic surgeon was performed, but this is a potential limitation of our study.
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Future Directions
Our study helps provide further evidence of an intrinsically altered immune
response in patients with RA. Validating these results with a larger cohort of patients
would be an important follow-up study. Increasing the sample size would not only help
increase the statistical power of the results, but also allow for further stratification of
patients on the basis of underlying diagnosis, treatment with TNF-inhibitors, or particle
burden and size without sacrificing on statistical validity.
In addition, the immunohistochemistry performed in this study was mainly
intended to corroborate the findings on light microscopy. As such the cell surface
markers used were meant to detect T lymphocytes, B lymphocytes, and plasma cells. As
discussed, however, other subsets of innate and adaptive immune system cells have been
implicated in RA. These would include activated macrophages, mast cells, Th1
lymphocytes, and Th17 cells, which can be detected by EMR1-F4/80, CD117, CD26, and
CD161 cell surface markers respectively[51-54]. Staining for these markers would
provide a better sense of the absolute numbers of these cells present in the tissue reaction
of RA patients, which could help further clarify the pathogenesis and natural history of
RA in the context of wear debris.
Furthermore, one of the potential clinical implications of this study is the
possibility of identifying new pharmacologic targets that could more effectively prevent
aseptic loosening from peri-prosthetic osteolysis in RA patients. Future studies could
examine the effectiveness of anti-plasma cell therapy. Such an approach might not only
reduce the production of anti-CCP antibodies but also reduce the known inflammatory
reaction induced by metallic wear debris. Medications such as bortezomib, which are
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used in the context of multiple myeloma, already exist. Moreover, although TNF
inhibitors appear to somewhat mitigate the inflammatory response seen in RA patients,
osteolysis is not significantly affected. In order to more directly prevent osteolysis,
pharmacologic targets could include the RANK/RANK ligand complex, IFN- γ, IL-17,
or inducible nitric oxide synthase activation.
Finally, examining some of the clinical and biomechanical factors that affect the
speed of implant failure would be another future direction. For instance, establishing the
prevalence of overuse syndromes in causing device failure would provide anticipatory
guidance in terms of counseling future arthroplasty patients with or without RA. Future
studies could also probe changes to the devices themselves to reduce the baseline
inflammatory response to wear debris. The lymphoplasmacytic response to foreign body
wear debris suggests that adjusting material choice, density, and manufacturing properties
could further mitigate the inflammatory response. Altering varus-valgus motion at the
prosthetic joint or the range of motion, for example, could also be explored in order to
decrease the speed of implant failure.

43
References
1.

Takemura, S., et al., T cell activation in rheumatoid synovium is B cell dependent.
J Immunol, 2001. 167(8): p. 4710-8.

2.

Lee, D.M. and M.E. Weinblatt, Rheumatoid arthritis. Lancet, 2001. 358(9285): p.
903-11.

3.

Cooles, F.A. and J.D. Isaacs, Pathophysiology of rheumatoid arthritis. Curr Opin
Rheumatol, 2011. 23(3): p. 233-40.

4.

James, E.A., et al., HLA-DR1001 presents "altered-self" peptides derived from
joint-associated proteins by accepting citrulline in three of its binding pockets.
Arthritis Rheum, 2010. 62(10): p. 2909-18.

5.

Snir, O., et al., Antibodies to several citrullinated antigens are enriched in the
joints of rheumatoid arthritis patients. Arthritis Rheum, 2010. 62(1): p. 44-52.

6.

van der Woude, D., et al., Gene-environment interaction influences the reactivity
of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat Genet,
2010. 42(10): p. 814-6; author reply 816.

7.

Padyukov, L., et al., A genome-wide association study suggests contrasting
associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann
Rheum Dis, 2011. 70(2): p. 259-65.

8.

Humby, F., et al., Ectopic lymphoid structures support ongoing production of
class-switched autoantibodies in rheumatoid synovium. PLoS Med, 2009. 6(1): p.
e1.

9.

Mahdi, H., et al., Specific interaction between genotype, smoking and
autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid
arthritis. Nat Genet, 2009. 41(12): p. 1319-24.

10.

Ding, B., et al., Different patterns of associations with anti-citrullinated protein
antibody-positive and anti-citrullinated protein antibody-negative rheumatoid
arthritis in the extended major histocompatibility complex region. Arthritis
Rheum, 2009. 60(1): p. 30-8.

11.

Shahrara, S., et al., TH-17 cells in rheumatoid arthritis. Arthritis Res Ther, 2008.
10(4): p. R93.

12.

Hueber, A.J., et al., Mast cells express IL-17A in rheumatoid arthritis synovium. J
Immunol, 2010. 184(7): p. 3336-40.

44
13.

Feldmann, M. and S.R. Maini, Role of cytokines in rheumatoid arthritis: an
education in pathophysiology and therapeutics. Immunol Rev, 2008. 223: p. 7-19.

14.

Elliott, M.J., et al., Randomised double-blind comparison of chimeric monoclonal
antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid
arthritis. Lancet, 1994. 344(8930): p. 1105-10.

15.

Paulus, H.E., et al., Analysis of improvement in individual rheumatoid arthritis
patients treated with disease-modifying antirheumatic drugs, based on the
findings in patients treated with placebo. The Cooperative Systematic Studies of
Rheumatic Diseases Group. Arthritis Rheum, 1990. 33(4): p. 477-84.

16.

van der Heide, A., et al., The effectiveness of early treatment with "second-line"
antirheumatic drugs. A randomized, controlled trial. Ann Intern Med, 1996.
124(8): p. 699-707.

17.

Donahue, K.E., et al., Systematic review: comparative effectiveness and harms of
disease-modifying medications for rheumatoid arthritis. Ann Intern Med, 2008.
148(2): p. 124-34.

18.

Saag, K.G., et al., American College of Rheumatology 2008 recommendations for
the use of nonbiologic and biologic disease-modifying antirheumatic drugs in
rheumatoid arthritis. Arthritis Rheum, 2008. 59(6): p. 762-84.

19.

Alonso-Ruiz, A., et al., Tumor necrosis factor alpha drugs in rheumatoid
arthritis: systematic review and metaanalysis of efficacy and safety. BMC
Musculoskelet Disord, 2008. 9: p. 52.

20.

Familian, A., et al., Infliximab treatment reduces complement activation in
patients with rheumatoid arthritis. Ann Rheum Dis, 2005. 64(7): p. 1003-8.

21.

Khraishi, M., Comparative overview of safety of the biologics in rheumatoid
arthritis. J Rheumatol Suppl, 2009. 82: p. 25-32.

22.

Bongartz, T., et al., Etanercept therapy in rheumatoid arthritis and the risk of
malignancies: a systematic review and individual patient data meta-analysis of
randomised controlled trials. Ann Rheum Dis, 2009. 68(7): p. 1177-83.

23.

Kapetanovic, M.C., et al., Orthopaedic surgery in patients with rheumatoid
arthritis over 20 years: prevalence and predictive factors of large joint
replacement. Ann Rheum Dis, 2008. 67(10): p. 1412-6.

24.

Lee, B.P., R.A. Adams, and B.F. Morrey, Polyethylene wear after total elbow
arthroplasty. J Bone Joint Surg Am, 2005. 87(5): p. 1080-7.

45
25.

Goldberg, S.H., et al., Modes of wear after semiconstrained total elbow
arthroplasty. J Bone Joint Surg Am, 2008. 90(3): p. 609-19.

26.

Wang, M.L., P.F. Sharkey, and R.S. Tuan, Particle bioreactivity and wearmediated osteolysis. J Arthroplasty, 2004. 19(8): p. 1028-38.

27.

Shanbhag, A.S., et al., Nitric oxide release by macrophages in response to
particulate wear debris. J Biomed Mater Res, 1998. 41(3): p. 497-503.

28.

Atkins, G.J., et al., Role of polyethylene particles in peri-prosthetic osteolysis: A
review. World J Orthop, 2011. 2(10): p. 93-101.

29.

Granchi, D., et al., The influence of alumina and ultra-high molecular weight
polyethylene particles on osteoblast-osteoclast cooperation. Biomaterials, 2004.
25(18): p. 4037-45.

30.

Gallo, J., et al., Bone remodeling, particle disease and individual susceptibility to
periprosthetic osteolysis. Physiol Res, 2008. 57(3): p. 339-49.

31.

Lohmann, C.H., et al., Nitric oxide and prostaglandin E2 production in response
to ultra-high molecular weight polyethylene particles depends on osteoblast
maturation state. J Bone Joint Surg Am, 2002. 84-A(3): p. 411-9.

32.

Willert, H.G., et al., Metal-on-metal bearings and hypersensitivity in patients with
artificial hip joints. A clinical and histomorphological study. J Bone Joint Surg
Am, 2005. 87(1): p. 28-36.

33.

Hallab, N.J., et al., Th1 type lymphocyte reactivity to metals in patients with total
hip arthroplasty. J Orthop Surg Res, 2008. 3: p. 6.

34.

Taki, N., et al., Polyethylene and titanium particles induce osteolysis by similar,
lymphocyte-independent, mechanisms. J Orthop Res, 2005. 23(2): p. 376-83.

35.

Goodman, S., Wear particulate and osteolysis. Orthop Clin North Am, 2005.
36(1): p. 41-8, vi.

36.

Caplan, A., Certain unusual radiological apperances in the chest of coal-miners
suffering from rheumatoid arthritis. Thorax, 1953. 8(1): p. 29-37.

37.

Kaufman, R.L., I. Tong, and T.D. Beardmore, Prosthetic synovitis: cinical and
histologic characteristics. Journal of Rheumatology, 1985. 12(6): p. 1066-1074.

38.

Goldring, S.R., et al., In patients with rheumatoid arthritis the tissue reaction
associated with loosened total knee replacements exhibits features of a
rheumatoid synovium. Journal of Orthopaedic Rheumatology, 1988. 1: p. 9-21.

46
39.

Hood, R.W., T.M. Wright, and A.H. Burstein, Retrieval analysis of total knee
prostheses: a method and its application to 48 total condylar prostheses. J
Biomed Mater Res, 1983. 17(5): p. 829-42.

40.

Casey, D., et al., PFC knee replacement: osteolytic failures from extreme
polyethylene degradation. Clin Orthop Relat Res, 2007. 464: p. 157-63.

41.

Kaufman, R.L., I. Tong, and T.D. Beardmore, Prosthetic synovitis: clinical and
histologic characteristics. J Rheumatol, 1985. 12(6): p. 1066-74.

42.

Campbell, P., et al., Histological features of pseudotumor-like tissues from metalon-metal hips. Clin Orthop Relat Res, 2010. 468(9): p. 2321-7.

43.

Hallab, N.J., et al., In vitro reactivity to implant metals demonstrates a persondependent association with both T-cell and B-cell activation. J Biomed Mater Res
A, 2010. 92(2): p. 667-82.

44.

Keegan, G.M., I.D. Learmonth, and C.P. Case, Orthopaedic metals and their
potential toxicity in the arthroplasty patient: A review of current knowledge and
future strategies. J Bone Joint Surg Br, 2007. 89(5): p. 567-73.

45.

Fujishiro, T., et al., Perivascular and Diffuse Lymphocytic Inflammation are not
Specific for Failed Metal-on-metal Hip Implants. Clin Orthop Relat Res, 2010.

46.

Caplan, A., R.B. Payne, and J.L. Withey, A broader concept of Caplan's
syndrome related to rheumatoid factors. Thorax, 1962. 17: p. 205-12.

47.

Corrigall, V.M. and G.S. Panayi, Autoantigens and immune pathways in
rheumatoid arthritis. Crit Rev Immunol, 2002. 22(4): p. 281-93.

48.

van de Sande, M.G., et al., Evaluating antirheumatic treatments using synovial
biopsy: a recommendation for standardisation to be used in clinical trials. Annals
of the Rheumatic Diseases.

49.

Schwarz, E.M., et al., Use of volumetric computerized tomography as a primary
outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic
osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J Orthop Res, 2003.
21(6): p. 1049-55.

50.

Klareskog, L., A.I. Catrina, and S. Paget, Rheumatoid arthritis. Lancet, 2009.
373(9664): p. 659-72.

51.

Khazen, W., et al., Expression of macrophage-selective markers in human and
rodent adipocytes. FEBS Lett, 2005. 579(25): p. 5631-4.

47
52.

Lu, L.F., et al., Mast cells are essential intermediaries in regulatory T-cell
tolerance. Nature, 2006. 442(7106): p. 997-1002.

53.

Willheim, M., et al., Cell surface characterization of T lymphocytes and allergenspecific T cell clones: correlation of CD26 expression with T(H1) subsets. J
Allergy Clin Immunol, 1997. 100(3): p. 348-55.

54.

Kleinschek, M.A., et al., Circulating and gut-resident human Th17 cells express
CD161 and promote intestinal inflammation. J Exp Med, 2009. 206(3): p. 525-34.

